MARKET WIRETradingView • 10h ago
INAB Q3'26 Earnings: revenue estimate is 0 USDTradingView report covering IN8bio Inc. (INAB) market action, institutional positioning, and fundamental catalysts.
Why INAB Stock dropped -8.04% Today — RQD Quant Desk Flash
$0.90 -8.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.89
IN8bio Inc. (INAB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $9.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on INAB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, IN8bio Inc. (NASDAQ: INAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.90 (-8.04% 1D, market cap $9.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INAB ranks #725 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does INAB compare to INTS and PASG in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.3M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for INAB?
▼
Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $0 in revenue, -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.89 (-1.64%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INAB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY INAB SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.23-11.4% Next Q
42
Q2 (-2Q)Grade E$1.09-11% Next Q
39
Q3 (-1Q)Grade E$0.97-7.2% Next Q
37
CurrentGrade E$0.90-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a INAB Turnaround Squeeze
While INAB currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($0.95) forces dealer call-delta covering toward $2.87.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INAB Stock dropped -8.04% Today — RQD Quant Desk Flash
IN8bio Inc. (INAB) dropped -8.04% to $0.90, trading at 2% of its 52-week range ($0.87 – $2.73). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.87 – $2.73) with RSI-14 at 40.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live INAB Headlines & Catalysts
MARKET WIREGlobeNewswire • 13h ago
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire report covering IN8bio Inc. (INAB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 16h ago
IN8bio stock has November 5, 2026 earnings datead-hoc-news.de report covering IN8bio Inc. (INAB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 41d ago
IN8bio to Present at Sidoti Small-Cap Virtual ConferenceNEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune d
MARKET WIREYahoo Finance • 54d ago
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & DevelopmentHeadshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appoin
MARKET WIREYahoo Finance • 88d ago
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAdvanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected i
MARKET WIREYahoo Finance • 116d ago
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed GlioblastomaFirst peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression
MARKET WIREYahoo Finance • 180d ago
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical ConferencesNEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and auto
MARKET WIREYahoo Finance • 179d ago
IN8bio Reports First Quarter 2026 Financial Results and Recent Business HighlightsAdvancing next-generation γδ T cell engager platform with initial animal data expected in 2026Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median ov
MARKET WIREYahoo Finance • 172d ago
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in GlioblastomaMultidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma Translational data
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INAB)
- ✓Walkthrough of INAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.10%🛡️ HOLDING TREND SUPPORT
2026-11-02O $1.02H $1.02L $0.90C $0.90VOL 1.4K
RES: $1.58SUP: $0.86SMA50: $1.15SMA200: $1.45
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on INAB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INAB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INAB)
Health Care Rank #725 of 1016
⚔️ INTS vs INAB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INAB vs. INTS, PASG, ATYR, BCDA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, IN8bio Inc. (INAB) ranks #725 by composite RQD confidence (34/100, grade E) and #898 by equity capitalization ($9.7M). Within this direct 5-issuer industry benchmark cohort, INAB leads on earnings valuation at N/A trailing P/E, while INAB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATYR currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with INAB at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INAB
ACTIVE
IN8bio Inc. | E | 34/100 | — | — | -35.0% | -8.04% | $9.7M | Benchmark Subject |
| INTS Intensity Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | +1.80% | $10.9M | /ints-vs-inab → |
| PASG Passage Bio Inc. | E | 34/100 | — | — | -35.0% | -1.99% | $11.3M | /pasg-vs-inab → |
| ATYR aTyr Pharma Inc. | D | 45/100 | — | — | -35.0% | -8.01% | $13.5M | /atyr-vs-inab → |
| BCDA BioCardia Inc. | D- | 38/100 | — | — | -35.0% | -7.02% | $14.0M | /bcda-vs-inab → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001740279In its most recent audited fiscal period (FY2025, filed 2025-12-31), IN8bio Inc. (INAB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.4M, operating cash flow of -$12.7M, and free cash flow of -$12.7M (+47.4% YoY). On the balance sheet, INAB closed FY2025 with $32.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$19.4M | -$12.7M | -$12.7M | $32.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$30.4M | -$24.1M | -$24.1M | $20.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$30.0M | -$23.3M | -$23.3M | — | — |
3. INAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, IN8bio Inc. (NASDAQ: INAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.90 (-8.04% 1D, market cap $9.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INAB ranks #725 in composite RQD confidence.
How does INAB compare to INTS and PASG in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.3M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INAB?
Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $0 in revenue, -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INAB trading relative to its 50-day, 200-day, and 52-week technical levels?
INAB last traded at $0.90 (-8.04% on volume of 47,936 shares), positioning the stock -21.74% below its 50-day simple moving average ($1.15) and -37.93% below its 200-day simple moving average ($1.45). Across its 52-week range of $0.87 to $2.73, INAB sits at the 1.6% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.01).
INAB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is INAB stock moving today?
Why INAB Stock dropped -8.04% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
INAB — IN8bio Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:52Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, INAB scores 34 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: Fundamental Cash Engine scores 8/20 (ROIC of -35%, FCF yield of 0%); Whale 13F Flow scores 3/20 (institutional accumulation and options positioning); Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 8/20 (Beta 1.0, sector sensitivity); and Forensic Balance Sheet scores 10/20 (Altman Z 2.5, Piotroski F 3/9, Debt/Equity 0.5).
For a prospective investor, the rating points to a company that is not currently generating cash returns, with negative ROIC and zero FCF yield. Weakest pillars are institutional flow and insider conviction, which suggests limited sponsorship from either source in the data provided. The forensic balance sheet pillar is the strongest of the five, but still scores only half its maximum. Any upside case would need to rest on factors outside the cash-generation and ownership signals captured here, and the source data does not identify those factors. The grade is a framework-based assessment and does not constitute personalized financial advice.
Recent Catalysts & News Wire Analysis
- Earnings timing: A TradingView item reports a Q3'26 earnings revenue estimate of 0 USD. A separate item states an earnings date of November 5, 2026.
- Nasdaq listing compliance: A GlobeNewswire item reports an inducement grant under Nasdaq Listing Rule 5635(c)(4).
- Signal flags: All three news items carry a YELLOW light and a MARKET WIRE impact label.
- Proprietary signals: Per the Butterfly Supply-Chain Graph, no proprietary signals are present.
Open Questions
- What is the company's cash and debt position by period, given that these fields are N/A in the SEC financials?
- What is the basis for the reported Q3'26 revenue estimate of 0 USD, and what drives the expected earnings timing?
- What are the terms and context of the Nasdaq Rule 5635(c)(4) inducement grant?
- What are the company's commercial programs, pipeline, or partnerships that could produce future revenue?
- What is the net share count and dilution history, which the source data does not provide?
INAB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for IN8bio Inc. (INAB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 10h ago
INAB Q3'26 Earnings: revenue estimate is 0 USD TradingView report covering IN8bio Inc. (INAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 13h ago
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire report covering IN8bio Inc. (INAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 16h ago
IN8bio stock has November 5, 2026 earnings date ad-hoc-news.de report covering IN8bio Inc. (INAB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 41d ago
IN8bio to Present at Sidoti Small-Cap Virtual Conference NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune d
🟡 MARKET WIRE Yahoo Finance • 54d ago
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appoin
🟡 MARKET WIRE Yahoo Finance • 88d ago
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected i
🟡 MARKET WIRE Yahoo Finance • 116d ago
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression
🟡 MARKET WIRE Yahoo Finance • 180d ago
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and auto
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
INAB Bull vs. Bear Conversation Board — What's Your Call at $0.90?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INAB 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.86 (-12.2%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is INAB (E • RQD 34/100) a Buy at $0.98?
Welcome to the INAB (IN8bio Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.79 (-19.4%)
Spot @ $0.98 Pump the brakes on INAB — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on INAB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless IN8bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.24 (+26.5%)
Spot @ $0.98 INAB cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on INAB, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.98 (52-wk range $0.87 - $2.73), any beat on forward guidance forces shorts and underweight funds to chase.